Anti-HER-3 antibodies such as MM-121 (http://ClinicalTrials.gov: NCT01451632), RG7116 (http://ClinicalTrials.gov: NCT01482377) and U3-1287 [40] are currently being tested in several clinical trials spanning various patient populations including CRC patients. The gene discussed is ERBB3; the disease is colorectal carcinoma.